Bruker AXS Launches New SuperSpeedSolutions-TM- for Materials Research and Nanostructure Applications.
Business Editors/Health/Medical Writers
MADISON, Wis.--(BUSINESS WIRE)--Jan. 13, 2004
Bruker AXS Inc., an operating company operating company
A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (Nasdaq: BRKR BRKR Breaker ), announced today the launch of a new series of X-ray diffraction (XRD XRD X-Ray Diffraction
XRD X-Ray Diode ) systems for materials research applications, named SuperSpeedSolutions(TM). Two novel technologies, the high-power Turbo-X-ray Source(TM) and the high-speed VANTEC-1(TM) detector based on brand new MikroGap(TM) technology, now enable X-ray diffraction to go beyond current limitations in terms of sensitivity and speed. Bruker AXS is starting to ship first systems in Q1/04.
The new Turbo-X-ray Source has been developed at Bruker AXS' new Yokahama R&D center which originated from the acquisition of MAC Science in 2002. The Turbo-X-ray Source is fully integrated into the D8 platform and shows outstanding sensitivity compared with other systems in the market. In combination with the new VANTEC-1 detector, or the existing HISTAR HISTAR Hyperspectral Imaging for Surveillance and Targeting (TM) detection system, it enables researchers to perform time-resolved X-ray diffraction experiments with milliseconds time resolution. The new SuperSpeedSolutions concept also includes systems for nanostructure analysis, by combining the recently launched NANOSTAR(TM) with the new Turbo-X-ray Source.
Frank Burgaezy, Managing Director and Business Unit Manager Materials Research, stated: "This is a major step forward in applying new X-ray technologies in the materials research market. In this 'three-continent' project our R&D teams in Madison, WI/USA, Karlsruhe/Germany and Yokohama/Japan have been working closely together, and the final outcome has even surpassed our highest expectations. We are proud that we can now offer the fastest and most sensitive X-ray laboratory diffraction system in the market, enabling our customers to tackle new applications in materials research and perform better and faster analyses on their current research targets."
Lutz Bruegemann, Marketing Manager for Materials Research, commented: "After demonstrating the outstanding analytical capabilities and the smart integration of our new SuperSpeedSolutions, we have so far received extremely positive feedback from our customers. Serving the entire materials research market from cutting-edge science to high-throughput industrial analysis, our SuperSpeedSolutions will not only extend our strong market position, but will also open new opportunities in market segments which were formerly not addressed by XRD."
Roger Durst, Vice President of R&D and Chief Technology Officer, added: "These exciting new products resulted from years of focused research by our global development team. We have married two powerful new technologies: our compact, high-intensity Turbo-X-ray Source delivers up to an order of magnitude A change in quantity or volume as measured by the decimal point. For example, from tens to hundreds is one order of magnitude. Tens to thousands is two orders of magnitude; tens to millions is three orders of magnitude, etc. more flux than conventional tubes while our breakthrough MikroGap detector technology features unprecedented quantum efficiency and counting rate performance. Together these tools allow existing experiments to be dramatically accelerated and also open up entirely new classes of time-resolved applications."
Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry mass spectrometry
or mass spectroscopy
Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. . Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending capital spending
Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.
When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K Form 10-K
A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information.
See 10-K. for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q Form 10-Q
See 10-Q. , our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.